Form 4: Akero Therapeutics CFO Sells Shares to Cover Tax Obligations

Akero Therapeutics, Inc.'s Chief Financial Officer, William Richard White, sold 1,634 shares of common stock in a non-discretionary transaction to cover tax withholding obligations.

Summary

• William Richard White, the Chief Financial Officer of Akero Therapeutics, Inc. (AKRO), sold 1,634 shares of the company's common stock.
• The transaction occurred on June 18, 2025, at a weighted-average price of $54.84 per share.
• The shares were sold in multiple transactions with prices ranging from $54.33 to $54.84.
• This sale was a 'sell-to-cover' transaction, meaning it was required to satisfy tax withholding obligations related to the vesting of restricted stock units.
• The sale was automatic and not at the discretion of Mr. White, consistent with the Issuer's adopted policy.
• Following this transaction, Mr. White beneficially owns 57,521 shares of Akero Therapeutics common stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transaction is a non-discretionary 'sell-to-cover' to satisfy tax obligations, which is a routine event and does not reflect management's discretionary view on the company's stock performance.

Future Outlook

The document, an SEC Form 4, does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Management Comments

• The Issuer has adopted a 'sell-to-cover' policy to satisfy the tax withholding obligations of the Reporting Person.
• Such sales were automatic and not at the discretion of the Reporting Person.

Industry Context

This Form 4 filing details a routine insider transaction for tax purposes and does not provide information relevant to broader industry trends or competitive landscape analysis.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine, non-discretionary sale for tax purposes and does not signal a change in management's confidence in the company.
• Employees: No direct impact mentioned.

Key Dates

Keywords

Akero Therapeutics, AKRO, SEC Form 4, Insider Trading, Stock Sale, Chief Financial Officer, William Richard White, Sell-to-Cover, Restricted Stock Units, Tax Withholding